MedTrace Logo

Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults

NCT06564207 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-02

No results posted yet for this study

Summary

This study is designed to evaluate the safety and efficacy of fostamatinib in hospitalized adult participants with acute respiratory distress syndrome (ARDS).

Conditions

  • Acute Respiratory Distress Syndrome
  • ARDS

Interventions

DRUG

Placebo

Placebo to be given twice daily for 14 days

DRUG

Fostamatinib

Fostamatinib 150mg to be given twice daily for 14 days

Sponsors & Collaborators

Principal Investigators

  • Christopher S. King, MD, FACP · Inova Schar Heart and Vascular

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-30
Primary Completion
2027-05-31
Completion
2027-10-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06564207 on ClinicalTrials.gov